Overview
BAY43-9006 Phase II Study for Renal Cell Carcinoma
Status:
Completed
Completed
Trial end date:
2006-03-01
2006-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate efficacy, safety, and pharmacokinetics of BAY 43-9006 in patients with unresectable and/or metastatic renal cell cancer (RCC) who have failed at least one cytokine containing regimen.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
BayerTreatments:
Niacinamide
Sorafenib
Criteria
Inclusion Criteria:- Patients who suffer from unresectable and/or metastatic, measurable RCC histologically
or cytologically documented.
- Patients with rare subtypes of RCC, such as pure papillary cell tumor, mixed tumor
containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or
chromophobe oncocytic tumors, are excluded from study participation.
Exclusion Criteria:
- More than three regimens of previous treatment for RCC